Baseline characteristics | Univariate | Multivariate |
---|---|---|
HR (95% CI; p value) | HR (95% CI; p value) | |
Calprotectin (μg/mL) | 2.38 (1.79–3.16; < 0.0001) | 2.74 (1.71–4.41; < 0.0001) |
Power Doppler score, 0–66 | 1.31 (1.18–1.45; < 0.0001) |  |
TNFi trough serum levels (μg/mL) | 0.47 (0.26–0.88; 0.018) | 0.36 (0.10–1.30; 0.120) |
DAS-ESR | 2.10 (0.72–6.18; 0.175) |  |
Time-to-remission (months) | 1.17 (1.11–1.23; < 0.0001) |  |
Time-in-remission (months) | 0.98 (0.97–1.00; 0.087) |  |
Female gender | 1.25 (0.38–4.15; 0.716) |  |
Disease duration (months) | 1.02 (0.96–1.08; 0.510) |  |
Diagnosis, RA/PsA | 2.39 (0.72–7.93; 0.155) | 0.80 (0.10–6.30; 0.832) |
Age (years) | 0.98 (0.94–1.03; 0.535) |  |
Monotherapy | 0.36 (0.10–1.33; 0.125) | 0.51 (0.08–3.35; 0.484) |
Steroids | 3.12 (1.02–10.1; 0.046) | 0.22 (0.04–1.21; 0.082) |